Loading clinical trials...
Loading clinical trials...
A 28 Week, Randomized, Double-blind, Placebo-controlled, Two-part, Multi-center, Parallel Group Dose Range Finding Study to Assess the Effect of Monthly Doses of Bimagrumab 70, 210, and 700 mg on Skeletal Muscle Strength and Function in Older Adults With Sarcopenia (InvestiGAIT)
Conditions
Interventions
bimagrumab
placebo
Locations
58
United States
Novartis Investigative Site
Little Rock, Arkansas, United States
Novartis Investigative Site
Cypress, California, United States
Novartis Investigative Site
La Jolla, California, United States
Novartis Investigative Site
Farmington, Connecticut, United States
Novartis Investigative Site
Gainesville, Florida, United States
Novartis Investigative Site
Miami, Florida, United States
Start Date
December 9, 2014
Primary Completion Date
June 26, 2018
Completion Date
June 28, 2018
Last Updated
January 5, 2021
NCT05884138
NCT06950125
NCT07412379
NCT06794853
NCT04869813
NCT06811324
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions